drugset / Trial / NCT00693862

Pharmacokinetic Study With Repeated Doses of Stalevo

NCT00693862

Phase 1 Completed 19 enrolled Orion Corporation, Orion Pharma
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to show that higher minimum concentration values are obtained following repeated doses of Stalevo 4 times daily compared to lecodopa/carbidopa treatment with corresponding dosing regimen.

Timeline

Start
2006-12
Primary completion
2008-04
Completion
2008-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbidopa Unknown
Subject Entacapone Small molecule
Subject Levodopa Small molecule

Indications

No indication recorded.